The series A funding round will be used to continue the development and marketing of Linkage Biosciences’s line of diagnostic products. The molecular diagnostics technologies and innovations will address human leukocyte antigen typing for organ transplantation, while further development is underway on a portfolio of products in other areas of transplantation and various complex genetic disorders, the company said.
The company has also announced that Rebecca Bishop and Pascal Villiger have joined the board of directors. Ms Bishop is currently a manager with Affymetrix, and Mr Villiger is an investment professional within the private equity division of CalSTRS.
Zachary Antovich, president and CEO of Linkage Biosciences, said: Our unique advantages are speed and simplicity while achieving superior accuracy. Our tests generate results much faster, with far less effort, than anything else available in the marketplace. We are pleased to have the support and experience of Greenhouse Capital and Jim Fisher as we begin to commercialize our products and expand our presence in the marketplace.